Medicine
Rizatriptan 5 mg orally disintegrating tablet
Rizatriptan 5 mg orally disintegrating tablet is a generic prescription medicine for oral use, made by 10 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store rizatriptan benzoate orally disintegrating tablets at 20 o to 25 • C (68…
Key facts
- Active ingredient (INN)
- Rizatriptan
- Brand
- Sold under the generic name
- Strength
- 5 mg
- Dosage form
- Orally disintegrating tablet
- Route
- Oral
- Packs
- 4 blister pack, 3 blister pack, 9 tablets and 25 more
- Manufacturers
- Macleods PharmaceuticalsIndiaAurobindo PharmaIndiaUnichem LaboratoriesIndiaGlenmark PharmaceuticalsIndiaPanacea BiotecIndiaGolden State Medical SupplyAsclemedBionpharmaChartwell RXRising Pharma Holdings
- Origin register
- US FDA, United States
- Storage
- Store rizatriptan benzoate orally disintegrating tablets at 20 o to 25 • C (68 o to 77 • F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CC04 Rizatriptan
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 July 2013
- Identifiers
- RxCUI 312837, 312839DailyMed set ID 3cdeccf6-36dd-4a9e-9687-2f7cce47af5f, 2337e102-8df0-4e7f-81d8-5cb86cd48674, 4de33a24-db69-444a-b04d-c69ccba57ab2 +7NDC 29300-268, 57237-085, 68462-467 +7Application ANDA207835, ANDA203062, ANDA201914 +3
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 65862-625-12 | Aurobindo PharmaIndia | 1 July 2013 |
| 3 blister pack in 1 carton / 6 tablet, orally disintegrating in 1 blister pack | 65862-625-18 | Aurobindo PharmaIndia | 1 July 2013 |
| 9 tablet, orally disintegrating in 1 bottle | 65862-625-36 | Aurobindo PharmaIndia | 5 March 2018 |
| 18 tablet, orally disintegrating in 1 bottle | 65862-625-48 | Aurobindo PharmaIndia | 5 March 2018 |
| 1 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 65862-625-64 | Aurobindo PharmaIndia | 28 August 2023 |
| 3 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 65862-625-90 | Aurobindo PharmaIndia | 1 July 2013 |
| 4 box in 1 carton / 3 pouch in 1 box / 1 blister pack in 1 pouch / 1 tablet, orally disintegrating in 1 blister pack | 68462-467-74 | Glenmark PharmaceuticalsIndia | 1 July 2013 |
| 12 tablet, orally disintegrating in 1 container | 33342-093-04 | Macleods PharmaceuticalsIndia | 27 February 2023 |
| 30 tablet, orally disintegrating in 1 container | 33342-093-07 | Macleods PharmaceuticalsIndia | 23 September 2014 |
| 10 blister pack in 1 carton / 10 tablet, orally disintegrating in 1 blister pack | 33342-093-12 | Macleods PharmaceuticalsIndia | 23 September 2014 |
| 18 tablet, orally disintegrating in 1 container | 33342-093-23 | Macleods PharmaceuticalsIndia | 27 February 2023 |
| 3 blister pack in 1 carton / 6 tablet, orally disintegrating in 1 blister pack | 33342-093-41 | Macleods PharmaceuticalsIndia | 4 June 2018 |
| 2 blister pack in 1 carton / 6 tablet, orally disintegrating in 1 blister pack | 33342-093-45 | Macleods PharmaceuticalsIndia | 19 December 2018 |
| 200 tablet, orally disintegrating in 1 container | 33342-093-46 | Macleods PharmaceuticalsIndia | 23 September 2014 |
| 4 pouch in 1 carton / 1 blister pack in 1 pouch / 10 tablet, orally disintegrating in 1 blister pack | 33342-093-48 | Macleods PharmaceuticalsIndia | 23 September 2014 |
| 1 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 33342-093-52 | Macleods PharmaceuticalsIndia | 13 February 2017 |
| 6 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 33342-093-72 | Macleods PharmaceuticalsIndia | 13 February 2017 |
| 3 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 33342-093-73 | Macleods PharmaceuticalsIndia | 13 February 2017 |
| 6 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 43817-133-04 | Panacea BiotecIndia | 17 January 2017 |
| 4 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 29300-268-21 | Unichem LaboratoriesIndia | 5 July 2017 |
| 6 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 29300-268-81 | Unichem LaboratoriesIndia | 5 July 2017 |
| 3 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 29300-268-91 | Unichem LaboratoriesIndia | 5 July 2017 |
| 6 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 69452-156-73 | Bionpharma | 17 January 2017 |
| 18 tablet, orally disintegrating in 1 bottle | 62135-998-17 | Chartwell RX | 26 August 2026 |
| 3 blister pack in 1 carton / 6 tablet, orally disintegrating in 1 blister pack | 57237-085-63 | Rising Pharma Holdings | 1 July 2013 |
| 3 blister pack in 1 carton / 6 tablet, orally disintegrating in 1 blister pack | 76420-908-18 | Asclemed | 27 January 2025 |
| 1 blister pack in 1 carton / 3 tablet, orally disintegrating in 1 blister pack | 51407-679-03 | Golden State Medical Supply | 28 September 2023 |
| 3 blister pack in 1 carton / 6 tablet, orally disintegrating in 1 blister pack | 51407-679-18 | Golden State Medical Supply | 28 September 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 June 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Rizatriptan
Clinical summary
Rizatriptan is a serotonin-1b and serotonin-1d receptor agonist indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old, among other approved uses. MedsAcross supplies Rizatriptan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RizatriptanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- MAXALT prescribing information (Organon) · U.S. National Library of Medicine, DailyMed
Need Rizatriptan 5 mg orally disintegrating tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.